Search
forLearn
5 / 801 resultslearn Lactobacillus
learn Pichia minuta yeast
learn Beta glucan
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Research
5 / 1000+ resultsresearch Mycobacteriosis in a Pet Ferret (Mustela putorius furo) Caused by Mycobacterium xenopi: A Case Report on Neglected Risk of Zoonotic Transmission
A pet ferret had a serious infection from Mycobacterium xenopi, which can spread to humans.
research Role of foxn1 in Xenopus laevis thymopoiesis.
FOXN1 is crucial for thymus development and immune response in Xenopus laevis.
research Sulfotransferases, sulfatases and formylglycine-generating enzymes: a sulfation fascination
The document concludes that understanding sulfation biology is crucial for creating treatments due to its importance in biological functions and disease.
research Identification of a Cyclosporine-Specific P450 Hydroxylase Gene through Targeted Cytochrome P450 Complement (CYPome) Disruption in Sebekia benihana
A gene in Sebekia benihana, CYP-sb21, is needed for a specific reaction on the drug Cyclosporine A, which could be important for hair growth without affecting the immune system.
research Baiting Proteins with C60
C60 fullerenes can alter protein function and may help develop new disease inhibitors.
Community Join
5 / 1000+ resultscommunity Kintor KX -826 Pyrilutamide Adds 1 Year Phase 3 Trial For Safety
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.
community day 107 of kx826 .5% . 1+ years on topical minoxidil.
The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.
community Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
community [Serious] Experience with grey-market KX-826 (Pyrilutamide)
The user experienced reduced hair loss using grey-market KX-826 alongside Minoxidil foam, achieving better results with Minoxidil liquid but restricted to foam due to an allergy. Initial side effects included shortness of breath, racing heart, and dizziness, which subsided after the first week.
community Kintor has released an investor relations memo regarding Chinese Phase III trials for Pyrilutamide
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.